TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: prevention of intrauterine adhesion formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) for MLN2480
Endpoint domain: Adverse events/effects
Primary endpoint: Recommended Phase 2 Dose (RP2D) of MLN2480
Endpoint domain: Adverse events/effects
Primary endpoint: remission after 8 weeks of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of bowel opacification as determined by estimated percentage of overall small bowel opacification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Degree of bowel distention as determined by measurement of the largest diameter, normal, small bowel loop in each of the four abdominal quadrants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: ColoRectal Functional Outcome
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Lower limb exercise capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of environmental pollutants (heavy metals, VOCs, PBDEs, phthalates)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin lesion area (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of new blisters/day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Pemphigoid Activity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: QoL: Physical Well-Being (FACT-L)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: General Fatigue (MFI)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Neurocognitive changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: 8-month iRANO-PFS
Endpoint domain: Mortality/survival
Primary endpoint: 12-month Overall Survival
Endpoint domain: Mortality/survival
Primary endpoint: Avoidable readmissions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean White Blood Cell (WBC) Cystine Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: incidence of treatment-related severe adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Breastfeeding Continuation Rates
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Rate of Emergency Room Visits in the First Year of Life
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Rate of adherence to AAP vaccination guideline in the First Year of Life
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body Weight Analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Freedom from severe SVD (structural valve deterioration)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cumulative ablation duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Reduction in the episodes of emesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduction in the intensity of nausea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: improvement in Visual Analogue Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sensitivity and specificity of CTP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PV-RQOL scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Success of fibroblast culture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with AED attached prior to EMS arrival
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum % Change in FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: radiographic failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Newcastle Paediatric Mitochondrial Disease Scale (NPMDS) Sections I-IV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful weaning from ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Readmission to Intensive Care Unit
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Absolute bioavailability of GSK1120212
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Treatment-Emergent Reactogenicity Events
Endpoint domain: Adverse events/effects
Primary endpoint: Response in Glucose AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Response in Insulin AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Response in Glucagon AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Gastric antral area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rate of participants with CR, PR, SD or PD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart contraction measured by MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: EEG spectral power
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Oxygen reserve index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Audiological Test Results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in HAMD-17 scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Solicited Local and Systemic Reactogenicity Adverse Reactions - First Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Solicited Local and Systemic Reactogenicity Adverse Reactions - Second Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Adverse Events of Special Interest and Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Neoadjuvant Rectal Cancer (NAR) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major Cytogenetic Response (MCyR) at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SF-12 Health assessment Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from baseline leisure-time physical activity at 12 months
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from baseline leisure-time physical activity at 18 months
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: AMPAC 6 Clicks Composite PT
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in severity of OCD symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of vaginal infections
Endpoint domain: Adverse events/effects
Primary endpoint: Non-inferiority of clopidogrel therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: CD8+ T cell infiltration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Responsiveness to passive leg raising
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of treatment emergent adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change of Equilibrium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of cases diagnosed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Total Cholesterol levels at 30 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline in LDL levels at 30 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline in Total Cholesterol levels at 60 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline in LDL levels at 60 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from mid-point in Total Cholesterol levels at 60 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: rheological measurements (viscosity and elasticity) in sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Any Death or Major Stroke in the First 30 Days
Endpoint domain: Mortality/survival
Primary endpoint: Neurologic Death or Ipsilateral Major Stroke Between Day 31 and Day 365
Endpoint domain: Mortality/survival
Primary endpoint: Complete Aneurysm Occlusion Assessed Using the WEB Occlusion Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of gliomas and related tumors
Endpoint domain: Mortality/survival
Primary endpoint: Change of Nerve Conduction Velocities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change of Nerve Conduction Latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change of Nerve Conduction Amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Medication management assessed by Medication Deficiency Checklist
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Area Under Curve (AUC0-t) for B17MP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bacterial load change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SVC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MUNE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Urethral and Anal Afferent Nerve Innervation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Motor Control as assessed by Fugl-Meyer assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Motor Control as assessed by Box and Block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Motor Control as assessed by Grip Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Bimanual activity quality as assessed by Task Completion Time
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Bimanual activity quality as assessed by Euclidean Distance
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Bimanual activity quality as assessed by Ovalization Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: improvement of frailty
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Rate of change in area of geographic atrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AOFAS-Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in brain neural activity during social reward processing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in resting state
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Brain network connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in fecal microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in fecal metabolome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of CKD-810 and Taxotere
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence and gravity of psychotic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prevalence and gravity of anxious symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prevalence and gravity of depressive symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean Gingival Plaque Units
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of genetic mutations in the TGFBI gene
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early recurrence rates
Endpoint domain: Mortality/survival
Primary endpoint: QRS Fragmentation Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement of amniotic fluid index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Mean Bias Between DigiVis and Standard Visual Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Linguistic performance amelioration ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum toxicity grades of Adverse Events (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Time to non-accidental death
Endpoint domain: Mortality/survival
Primary endpoint: Change of Maximum Pain During Contraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of postnatal depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: psychological and general well-being index
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Plasma Phylloquinone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Patient satisfaction at one year
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Oswestry questionnaire (lumbar pathology)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Visual Analog Scale (Pain)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Classic score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive Emotion
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: anti-HBs antibody concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: incidence of immobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Meeting Serotype-specific Immunoglobulin G (IgG) Threshold Value of ≥0.35 μg/mL 30 Days After Dose 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Concentration (GMC) of Serotype-specific Immunoglobulin G (IgG) 30 Days After Dose 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Intensity of the MRI Signal in the Left Temporal Precentral Zone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in toxicity of faecal water
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Degree of protein assimilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence and severity of deep vein thrombosis (DVT) and pulmonary embolism (PE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Gene expression of cancer antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: preoperative baseline cervical dilatation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Intensity of pain in epicondylitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recurrence after the first episode of diverticulitis
Endpoint domain: Mortality/survival
Primary endpoint: 60-day ≥ Grade II Complication Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction of pain/discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Self-efficacy to exercise
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Estimated energy expenditure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Cloze Reading Comprehension
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Passage Reading Comprehension Study 1 only
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Word Reading
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Decoding
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Reading Fluency
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Phonological Processing Blending Study 1 only
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: AUC0-tau,ss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ctau,ss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with decreased cardiometabolic risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Average sputum production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of patients with negative biopsy results
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Complete Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRSA decolonization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: molecular relapse-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Basal inflammatory marker assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Clinical symptom severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bang Blinding Index (BI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent increase of absolute lymphocyte count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: QoL Measurements Using FACT-HEP Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Rate of Glucose Disposal (RD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Weight From Baseline at 12 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Body Mass Index From Baseline at 12 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Percent Fat Mass From Baseline in 12 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Fat Free Mass From Baseline at 12 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in fetal hemoglobin (HbF) from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Plasma isoprostanes/isofurans
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily voiding diary
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Quality of Life (QoL) questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: AUC From Time Zero Extrapolated to Infinity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Rosenberg Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Movement Disorders Society Unified Parkinson's Disease Rating Scale Part III Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Feasibility and acceptability of using the telehealth system
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: CD34+ cells function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with very premature coronary artery disease treated
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: AYA illness-related distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Parent quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: AYA resilience
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Toxicities of the treatment regimen
Endpoint domain: Adverse events/effects
Primary endpoint: Feasibility of the treatment regimen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean pelvic rotation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Fibromyalgia pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: suppressed arousal
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidences of student performed dental treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes